IL-7 armed binary CAR T cell strategy to augment potency against solid tumors
IntroductionClinical studies of T cells engineered with chimeric antigen receptor (CAR) targeting CD19 in B-cell malignancies have demonstrated that relapse due to target antigen (CD19) loss or limited CAR T cell persistence is a common occurrence. The…